Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Seaport Therapeutics reported Q1 2026 results with a net loss of $25.4 million, driven by increased R&D spend of $21.4 million as its lead programs advance. The company highlighted positive clinical progress: GlyphAgo showed a 6.8-fold increase in bioavailability compared to unmodified agomelatine, potentially avoiding liver toxicity issues, while enrollment in the pivotal Phase 2b BUOY-1 trial for GlyphAllo is on track with topline data expected in H1 2027. Seaport closed an upsized IPO raising $260 million in gross proceeds, bringing total cash and investments to over $470 million and extending its operational runway into 2029. Dr.
Key figures
- Revenue
- 0
- Net loss
- 25408000
- Ga expenses
- 6112000
- Rd expenses
- 21431000
- Runway year
- 2029
- Ipo proceeds
- 260000000
- Cash and investments
- 212642000
- Glyphallo target enrollment
- 360
- Glyphago bioavailability increase
- 6.8-fold
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.